| Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 6. CD
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 CRISPR
NF33-39 (in situ)
|
|
|
|
Fig.1.C,D
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
Fig.6.B,C
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
|
Fig.1.E,F
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|